...A. So of course, pharma is not the totality of Aptar, but it is our largest business and about two-thirds of our EBITDA, going on 70%. B. Just some highlights, almost 100% of our energy is renewable source. C. We're more closer to 1 times levered. D. As I said, more than 50% goes to the Pharma business, both on CapEx and acquisition. E. And we -- on this particular time frame from 2019 through the first nine months of 2024, we invested about 70% in the business organically and inorganically, and we returned 30% to shareholders through dividends and buybacks. F. About 18 months ago, we raised our long-term targets primarily on the back of the strength of our Pharma business. G. We raised the long-term top-line growth target by 100 basis points to 7% to 11%. H. Actually, we've been 8% for more than the last decade. I. We raised the profitability target for the company by 100 basis points to 21% to 23%. J. We raised the return on invested capital by 100 basis points from -- to 11% to 13%....
